Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3729020 | 0.82 | SMN1; SMN2 (0.38) | GPR88SMN1; SMN2L3MBTL1SMYD3KMT2A | |
| SCHEMBL3719801 | 0.82 | SMN1; SMN2 (0.38) | GPR88SMN1; SMN2L3MBTL1SMYD3KMT2A | |
| SCHEMBL11985449 | 0.78 | SMYD3 (0.42) | GPR88SMN1; SMN2L3MBTL1SMYD3KMT2A | |
| SCHEMBL14416477 | 0.78 | ALDH1A1 (0.50) | SMN1; SMN2LMNAEPHX1 | |
| SCHEMBL1445829 | 0.77 | SMYD3 (0.41) | GPR88SMN1; SMN2L3MBTL1SMYD3KMT2A | |
| SCHEMBL1464146 | 0.77 | SMYD3 (0.41) | GPR88SMN1; SMN2L3MBTL1SMYD3KMT2A | |
| SCHEMBL1445966 | 0.77 | SMYD3 (0.41) | GPR88SMN1; SMN2L3MBTL1SMYD3KMT2A | |
| Hydrochloric Acid SCHEMBL1464088 | 0.76 | SMYD3 (0.40) | GPR88SMN1; SMN2L3MBTL1SMYD3KMT2A | |
| Hydrochloric Acid SCHEMBL1445815 | 0.76 | SMYD3 (0.40) | GPR88SMN1; SMN2L3MBTL1SMYD3KMT2A | |
| SCHEMBL14975157 | 0.75 | L3MBTL1 (0.43) | GPR88L3MBTL1SMYD3KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247532-B2 | Deuterated hepatitis C protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-21 | — | — | US | disclosed |
| EP-2194039-A1 | Process for preparing optically enriched compounds | Vertex Pharmceuticals Incorporated (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20070225297-A1 | Deuterated hepatitis C protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225297-A1 | Deuterated hepatitis C protease inhibitors | PEPD, CTRL, CTSC | GPR88 2451/4885SMN1; SMN2 4416/4885L3MBTL1 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.